Glenmark Pharmaceuticals Ltd

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2260.5, up 2.24% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.68% on the day, quoting at 24436.8. The Sensex is at 78319.33, up 0.71%. Glenmark Pharmaceuticals Ltd has gained around 3.86% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 6.64% in last one month and is currently quoting at 25745.15, up 0.02% on the day. The volume in the stock stood at 3.7 lakh shares today, compared to the daily average of 5.9 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 2272.5, up 2.24% on the day. Glenmark Pharmaceuticals Ltd is up 21.53% in last one year as compared to a 4.02% slide in NIFTY and a 15.14% slide in the Nifty Pharma index.The PE of the stock is 38.97 based on TTM earnings ending March 26.Powered by Capital Market - Live

The company said the product is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa IntraMuscular Injection 10 mg/vial, marketed by Cheplapharm Registration GmbH under NDA 021253. According to IQVIA sales data for the 12-month period ended May 2026, the reference product recorded annual sales of approximately $25.4 million in the US. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'The launch of Olanzapine for Injection underscores our strategic focus on growing a robust injectable portfolio and strengthening our presence within the institutional channel. It reflects our continued commitment to expanding access to quality and affordable treatment options to meet the evolving needs of patients and healthcare providers.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Olanzapine for Injection, 10 mg/vial, Single-Dose Vial. Glenmark's Olanzapine for Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Zyprexa'2 IntraMuscular Injection 10 mg/vial, of Cheplapharm Registration GmbH [NDA 021253]. According to IQVIA' sales data for the 12-month period ending May 2026, the Zyprexa' IntraMuscular Injection market achieved annual sales of approximately $25.4 million.

Glenmark Specialty S.A, a wholly owned subsidiary of Glenmark Pharmaceuticals (Glenmark) announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan (SHR-A1811), a HER2-targeted antibody drug conjugate (ADC), for patients with platinum-resistant ovarian cancer (PROC). India will serve as the first country in Glenmark's licensed markets to initiate patient enrollment for the Phase 3 clinical trial, following the approval of Drugs Controller General of India (DCGI). Glenmark also plans to enroll patients in Australia and South Korea, subject to regulatory approvals. The study is aligned with Jiangsu Hengrui Pharmaceuticals Co.'s ongoing parent Phase 3 trial in China. Glenmark aims to generate clinically relevant data across broader and more diverse patient populations, supporting the development of Trastuzumab rezetecan across Glenmark's licensed markets. The randomized, controlled, multi-centre, Phase 3 trial is designed to evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab rezetecan in patients with HER2-expressing platinum-resistant ovarian cancer, a difficult-to-treat disease where treatment options remain limited, and outcomes continue to be poor. Conducting the trial across multiple geographies is expected to support the generation of evidence from diverse patient groups and strengthen the clinical data package for the therapy across Glenmark's licensed markets.

The company said its product is bioequivalent and therapeutically equivalent to ProvayBlue Injection, 50 mg/10 mL (5 mg/mL), the reference listed drug of Provepharm SAS. Citing IQVIA sales data, Glenmark noted that the ProvayBlue injection market recorded annual sales of about $19 million for the 12-month period ended April 2026. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'the launch of Methylene Blue Injection USP reflects Glenmark's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. The counter fell 1.31% to Rs 2,128.50 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced the launch of Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single Dose Vial. Glenmark's Methylene Blue Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, ProvayBlue' Injection, 50 mg/10 mL (5 mg/mL), of Provepharm SAS [NDA 204630]. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'The launch of Methylene Blue Injection USP reflects Glenmark's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve. This addition further strengthens our institutional portfolio and reinforces our focus on delivering reliable treatment options across the U.S. market.'

The launch follows the European Commission's marketing authorisation granted to Cassiopea S.p.A., a subsidiary of Cosmo N.V., in October 2025 for use in adults and adolescents aged 12 to under 18 years, with adolescent use limited to facial application. Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain. In Portugal, the product is being introduced through a strategic partner. The company is also advancing additional launches through strategic partnerships across other European markets. The product is approved in the European Union for the treatment of acne vulgaris in both adults and adolescents. It has been developed by Cassiopea, which holds the rights across Europe and works with regional partners for commercialisation. Acne vulgaris is one of the most common dermatological conditions globally, with more than 95% of males and 85% of females experiencing it during adolescence. Around 50% of individuals continue to experience acne into adulthood. The condition can have significant physical and psychological effects, particularly among adolescents and young adults. Winlevi is the first topical acne therapy in over 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is a topical androgen receptor inhibitor that works locally in the sebaceous glands to reduce sebum production and inflammation without systemic anti-androgen effects, supporting safe use in both males and females. The availability of the therapy provides an additional treatment option for healthcare professionals and patients across Europe. The launch marks an important milestone in Glenmark's dermatology growth strategy and reflects its continued focus on expanding access to differentiated therapies across global markets. It also strengthens the company's ability to execute multi-market launches in Europe through a combination of direct presence and strategic partnerships. Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented, 'The European launch of Winlevi' represents an important milestone for Cosmo and reflects the strength of our collaboration with Glenmark. This achievement supports our strategy of expanding the global reach of our innovative dermatology portfolio through trusted partnerships and disciplined execution. We are pleased to see Winlevi' becoming available to patients across Europe and look forward to continuing to build on the momentum of our long-term partnership with Glenmark.' Jiri Havranek, Group Vice President & Business Head ' Europe, Glenmark Pharmaceuticals, commented, 'This launch is an important step in strengthening Glenmark's dermatology portfolio and advancing our branded business in the region. As Glenmark's first NCE launch in Europe, it reflects our focus on bringing differentiated treatment options to patients through disciplined execution, strong market access alignment and meaningful partnerships. We remain committed to expanding access to therapies that address unmet needs and support better outcomes for patients.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. The counter rose 0.39% to Rs 2,152.50 on the BSE. Powered by Capital Market - Live

 Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals, today announced the launch of Winlevi' (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to 18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V. (SIX: COPN) (Cosmo) in October 2025. Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain. In Portugal, the Company has launched the product through a strategic partner. Glenmark is also advancing additional launches through strategic partnerships across other European markets. The product is authorized in the European Union for the treatment of acne vulgaris in adults and adolescents. The product has been developed by Cassiopea, which holds rights across Europe and collaborates with regional partners for commercialization.

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB Inc. According to IQVIA sales data for the 12-month period ended April 2026, the Vimpat Injection market recorded annual sales of approximately $15.2 million in the United States. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, 'The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. Shares of Glenmark Pharmaceuticals rose 0.18% to Rs 2185.30 on the BSE.Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark's Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat'2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA' sales data for the 12-month period ending April 2026, the Vimpat' Injection market3 achieved annual sales of approximately $15.2 million. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.'